AMCP Press & News

AMCP has selected Boyang Dong, PharmD candidate at Purdue University, as its 2025–2026 Executive Fellow in Health Care Association Leadership. This year-long program offers pharmacists structured and immersive experiences in association management and managed care pharmacy leadership.

A new Academy of Managed Care Pharmacy Foundation report, “Emerging Trends Impacting Managed Care Pharmacy,” developed in partnership with Pfizer, warned of significant shifts within managed care pharmacies fueled by AI adoption, drug shortages and affordability challenges.

This year, there may be two or more overlapping budget packages likely to contain some of the most significant legislation of 2025. AMCP’s Adam Colborn analyzes how these bills are different and what they mean for managed care and health care broadly. Read more:

With President Trump and his administration returning to Washington, D.C., and a new Congress set to take shape, there’s naturally some uncertainty when it comes to the future of American health care policy. Looking ahead to 2025, however, there will likely be some key decisions affecting and defining how managed care pharmacy and the larger health care system operate and serve patients.

AMCP's Journal of Managed Care + Specialty Pharmacy (JMCP) December 2024 Issue

AMCP's Journal of Managed Care + Specialty Pharmacy (JMCP) December 2024 Issue

Our Associate Vice President of Congressional Affairs Adam Colborn unpacks the key issues the health policy community should be on watch for when preparing for the incoming presidential administration in a recent article for First Report Managed Care.

AMCP CEO Susan Cantrell stresses how collaboration is key in addressing challenges such as high drug prices and healthcare disparities. While there’s no silver bullet, solutions such as tailored population benefit design and value-based contracting can play an important role in making a difference for ordinary Americans looking for affordable access to prescriptions.

Hernandez co-authored a June study in the Journal of Managed Care & Specialty Pharmacy (JMCP) on price benchmarks for selected drugs and their therapeutic alternatives, which concluded different negotiation scenarios for the first 10 drugs. If a drug has a therapeutic alternative, that likely guided the initial price offer from the CMS.

Because most prescription drugs selected for negotiation are highly rebated and discounted—prior to the federal government negotiations—comparisons of MFPs with list prices are somewhat misleading. Many of the ten drugs chosen already had significant rebates, in some cases as high as 68% off of the wholesale acquisition cost.